A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Katrien Berns,Hugo M. Horlings,Bryan T. Hennessy,Mandy Madiredjo,E. Marielle Hijmans,Karin Beelen,Sabine C. Linn,Ana M. Gonzalez-Angulo,Katherine Stemke-Hale,Michael Hauptmann,Roderick L. Beijersbergen,Gordon B. Mills,Marc J. van de Vijver,René Bernards +13 more
1.6K
TL;DR: Assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone.
read more
About: This article is published in Cancer Cell. The article was published on 16 Oct 2007. and is currently open access. The article focuses on the topics: Trastuzumab & Breast cancer.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Metabolic Changes and Their Characterization
Noor-ul Ain,Hira Gull +1 more
- 01 Jan 2020
TL;DR: The current chapter sequentially discusses various cancer associated-metabolic mechanisms, drug resistance patterns, and functioning of various regulatory genes associated with metastasis, followed by a brief account of various therapeutic and dietary options which have validated potential in confronting these metabolic changes and, in turn, impeding cancer growth and proliferation.
3
Novel Therapeutic Strategies and Combinations for HER2-Overexpressing Breast Cancer
Sylvia Shabaya,Rita Nahta +1 more
- 09 Nov 2011
TL;DR: Resistance to clinically available HER2-targeted agents is a major concern in the treatment of patients with HER2overexpressing metastatic breast cancer.
•Dissertation
Hitting cancer where it hurts most
H.J. Kuiken
- 13 Sep 2012
TL;DR: This thesis describes three distinct studies in which functional genomic screens based on RNA interference have been employed to identify cancer cell specific dependencies, genes involved in therapy response and regulators of a key signalling network that is often deregulat ed in cancer.
3
•Dissertation
Investigations of the telomerase template antagonist grn163l and implications for augmenting breast cancer therapy
Erin M. Goldblatt
- 01 Jan 2008
TL;DR: It is suggested that within the context of a youth-services agency using mobile devices, using a tablet or computer is more beneficial than using a traditional hand-magnifying lens for the diagnosis of mental health problems.
3
Cancer Biology and the Principles of Targeted Cancer Drug Discovery
P. Hillmann,D. Schmitz,J. Mestan,S. D’Alonzo,D. Fabbro +4 more
- 01 Jan 2017
TL;DR: An overview of different fields of targeted cancer drug discovery and strategies to validate novel targets and biomarkers is given.
3
References
edgeR: a Bioconductor package for differential expression analysis of digital gene expression data.
TL;DR: EdgeR as mentioned in this paper is a Bioconductor software package for examining differential expression of replicated count data, which uses an overdispersed Poisson model to account for both biological and technical variability and empirical Bayes methods are used to moderate the degree of overdispersion across transcripts, improving the reliability of inference.
39.8K
MicroRNAs: Genomics, Biogenesis, Mechanism, and Function
TL;DR: Although they escaped notice until relatively recently, miRNAs comprise one of the more abundant classes of gene regulatory molecules in multicellular organisms and likely influence the output of many protein-coding genes.
36.3K
MicroRNAs: Target Recognition and Regulatory Functions
TL;DR: The current understanding of miRNA target recognition in animals is outlined and the widespread impact of miRNAs on both the expression and evolution of protein-coding genes is discussed.
20.3K
Molecular portraits of human breast tumours
Charles M. Perou,Therese Sørlie,Michael B. Eisen,Matt van de Rijn,Stefanie S. Jeffrey,Christian A. Rees,Jonathan R. Pollack,Douglas T. Ross,Hilde Johnsen,Lars A. Akslen,Øystein Fluge,Alexander Pergamenschikov,Cheryl A. Williams,Shirley Zhu,Per Eystein Lønning,Anne Lise Børresen-Dale,Patrick O. Brown,David Botstein +17 more
TL;DR: Variation in gene expression patterns in a set of 65 surgical specimens of human breast tumours from 42 different individuals were characterized using complementary DNA microarrays representing 8,102 human genes, providing a distinctive molecular portrait of each tumour.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
12.4K
Related Papers (5)
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more